EUVIMEDEUVIMED entdecken
Crossref

CON: Dose-dense Paclitaxel at 80 mg/m2 Weekly in Combination with Carboplatin AUC-6 Every Three Weeks Should Not be Considered Standard of Care in the Front Line Management of Ovarian Cancer

Robert Mannel

Clinical Ovarian Cancer · 2011

DOI: 10.1016/j.cloc.2011.04.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von Robert Mannel. Die Arbeit nennt 13 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Mannel, R. (2011). CON: Dose-dense Paclitaxel at 80 mg/m2 Weekly in Combination with Carboplatin AUC-6 Every Three Weeks Should Not be Considered Standard of Care in the Front Line Management of Ovarian Cancer. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2011.04.010

Vancouver

Mannel R. CON: Dose-dense Paclitaxel at 80 mg/m2 Weekly in Combination with Carboplatin AUC-6 Every Three Weeks Should Not be Considered Standard of Care in the Front Line Management of Ovarian Cancer. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2011.04.010

BibTeX
@article{Mannel2011,
  author = {Mannel, Robert},
  title = {CON: Dose-dense Paclitaxel at 80 mg/m2 Weekly in Combination with Carboplatin AUC-6 Every Three Weeks Should Not be Considered Standard of Care in the Front Line Management of Ovarian Cancer},
  journal = {Clinical Ovarian Cancer},
  year = {2011},
  doi = {10.1016/j.cloc.2011.04.010}
}
Kostenlos starten →